Seeking Alpha

Amgen Inc. (AMGN)

  • Apr. 24, 2012, 5:11 PM
    More on Amgen (AMGN): Q1 beats across the board on strong sales growth and better margins. Combined sales of Neulasta and Neupogen +9%, Xgeva +14%, and Prolia +9%. Operating margins rose to 36.4% from 34.9%.
    | Comment!
  • Apr. 24, 2012, 4:13 PM
    Amgen (AMGN): Q1 EPS of $1.61 beats by $0.16. Revenue of $4.05B (+9% Y/Y) beats by $120M. (PR)
    | Comment!
  • Apr. 10, 2012, 8:52 AM
    Amgen (AMGN) acquires privately-held KAI Pharmaceuticals for $315M in a deal that will give it widespread rights for kidney disease treatment KAI-4169. As part of the agreement between the firms, Amgen has provided a loan to enable Phase 3 clinical development planning for KAI-4169 prior to the transaction closing.
    | Comment!
  • Apr. 2, 2012, 4:39 PM
    Amgen (AMGN) and AstraZeneca (AZN) have agreed to collaborate on the development and commercialization of 5 drugs in Amgen's clinical inflammation porfolio. AstraZeneca will lead the way in developing 3 of the 5 drugs.  AstraZeneca will make a $50M one-time payment to Amgen, as well as royalty payments following commercialization.
    | 1 Comment
  • Mar. 27, 2012, 3:12 PM
    Affymax (AFFY +10.9%) shares resume trading, popping more than 10% after the company confirms the FDA cleared the company's peginesatide anemia treatment for patients on dialysis for chronic kidney disease. The drug will be AFFY's first marketed product. Competitor Amgen (AMGN +0.5%) also trades higher.
    | Comment!
  • Mar. 26, 2012, 12:14 PM
    Results from a Phase II trial of a cholestoral drug from Regeneron (REGN +0.7%) were good but were upstaged at a heart conference by the outcome of a Phase I trial of a rival treatment from Amgen (AMGN +1.5%), which was better. Still, both drugs have a long way to go before they'll be able to enter a market that could be worth $20B/year.
    | Comment!
  • Mar. 26, 2012, 6:53 AM
    Amgen (AMGN) announces positive results from a study of its cholesterol-fighting human monoclonal antibody AMG 145. The treatment reduces so-called bad cholesterol by up to 81%, according to data. Phase II results are due out later this year as Amgen tries to shoulder into the high-stakes Lipitor vs. generics battle.
    | Comment!
  • Mar. 15, 2012, 1:31 PM
    Affymax (AFFY +4%) makes new 52-week highs after Stifel upgrades shares to Buy. The firm expects Affymax's Peginesatide dialysis drug, which is set for a Q2 launch, to be "a disruptive force" in its target market, one that will put an end to the "monopoly pricing power" wielded by Amgen's (AMGN) Epogen.
    | Comment!
  • Mar. 7, 2012, 4:58 PM
    Eight big drugmakers - ABT, AMGN, AZN, BMY, GSK, MRK, NVS, PFE - are sued by a consumer group claiming the companies’ coupon programs, which cover much of the patient co-payment for hundreds of brand-name prescription medicines, are illegal.
  • Mar. 6, 2012, 11:16 AM
    Amgen (AMGN -1%) dips after being cut to Market Perform on valuation at Bernstein, citing looming competition in 2013.
    | Comment!
  • Feb. 9, 2012, 11:07 AM
    Amgen (AMGN -1.2%) continues its slide on the back of the FDA's rejection of Xgeva yesterday, spurred on today by a downgrade to Perform at Oppenheimer, citing a lack of near-term catalysts for the drug maker over the near term.
    | 1 Comment
  • Feb. 8, 2012, 1:17 PM
    BMO Capital weighs in on the FDA rejection of Amgen's (AMGN -1.3%) Xgeva cancer drug, saying that if the firm fails to ultimately win approval for use of the drug it could lose revenue of as much as $1B.
    | Comment!
  • Feb. 8, 2012, 12:16 PM
    An FDA panel has voted 12-1 against expanded use of Amgen's (AMGN -1.2%) Xgeva for prostate cancer bone met prevention, according to a Bloomberg report. (pdf)
    | Comment!
  • Jan. 26, 2012, 4:27 PM
    More on Amgen (AMGN): Q4 misses slightly on a per share basis due to higher sales costs, but beats on revenue. Overall sales growth was positive, with strong performance coming from its two heavyweight drugs, Xgeva and Prolia, plus decent showings as well from Neupogen and Neulasta. The Company expects FY12 revenue in the range of $16.1B - $16.5B. Shares +0.8% AH.
    | Comment!
  • Jan. 26, 2012, 4:10 PM
    Amgen (AMGN): Q4 EPS of $1.21 misses by $0.01. Revenue of $3.97B (+4% Y/Y) beats by $60M. (PR)
    | Comment!
  • Jan. 26, 2012, 8:35 AM
    Micromet (MITI) surges 34% to $11.07, which is just above Amgen's (AMGN) $11/share offer for the company.
    | 1 Comment
Visit Seeking Alpha's
AMGN vs. ETF Alternatives
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States